Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Fineline Cube Apr 27, 2026
Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Fineline Cube Apr 27, 2026
Company Drug

HutchMed’s Elunate Receives NMPA Review for Second-Line Gastric Cancer Treatment

Fineline Cube Apr 18, 2023

China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that the National Medical Products Administration (NMPA)...

Company Drug

HuidaGene Receives CDE IND Approval for Ophthalmology Gene Therapy HG004

Fineline Cube Apr 18, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...

Company Drug

CBMG’s C-CAR031 Shows Promising Results in Phase I Study for Hepatocellular Carcinoma

Fineline Cube Apr 18, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has published the results of the...

Company

CanSino Biologics Reports 2022 Revenue Drop and Increased Losses Amid COVID-19 Vaccine Market Shifts

Fineline Cube Apr 18, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has released its 2022 financial report, recording...

Company Deals

PackGene Secures Series C Financing to Boost AAV Innovation and Global Expansion

Fineline Cube Apr 18, 2023

China-based PackGene Biotech has announced the successful completion of a Series C financing round, securing...

Company Deals

Bioworkshops Secures RMB 100 Million in Series A Financing for Biologic Drug Development

Fineline Cube Apr 18, 2023

Bioworkshops, a Contract Development and Manufacturing Organization (CDMO) based in Suzhou and specializing in biologic...

Company Medical Device

Sinovation Medical’s SinoLITT System and Fiber Kit Gain NMPA Approval for Epilepsy Treatment

Fineline Cube Apr 18, 2023

Sinovation (Beijing) Medical Technology Co., Ltd has announced that its in-house developed magnetic resonance monitoring...

Company R&D

Merck and XtalPi Leverage Molecular Dynamics to Enhance Small-Molecule Crystallization

Fineline Cube Apr 17, 2023

German pharmaceutical giant Merck (NYSE: MRK) and China-based drug discovery solutions specialist XtalPi have published...

Company Drug

Neurophth Biotechnology Receives NMPA Approval for Phase I/II Gene Therapy Study

Fineline Cube Apr 17, 2023

Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced that it...

Company Deals

Shenzhen Core Medical Technology Secures RMB 200 Million in Series C+ Financing for Artificial Heart Tech

Fineline Cube Apr 17, 2023

Shenzhen Core Medical Technology Co., Ltd, a leading Chinese manufacturer of artificial hearts, has reportedly...

Company Drug

Hainan Poly Pharm Wins Health Canada Approval for Generic Cytovene-IV (Ganciclovir)

Fineline Cube Apr 17, 2023

Hainan Poly Pharm Co., Ltd (SHE: 300630), a China-based pharmaceutical company, has announced that it...

Company Deals

Zephyrm Bioscience Secures Over RMB 200 Million in Series B Financing for Stem-Cell Drug Development

Fineline Cube Apr 17, 2023

Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more...

Company Deals

Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply

Fineline Cube Apr 17, 2023

Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical...

Company Drug

CanSino Biologics Receives NMPA Approval for Bivalent COVID-19 mRNA Vaccine

Fineline Cube Apr 17, 2023

CanSino Biologics Inc., a leading Chinese vaccines specialist, has announced that it has received clinical...

Company Drug

JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC

Fineline Cube Apr 17, 2023

JS InnoPharm Ltd, a Shanghai-based pharmaceutical company, announced that the first patient has been dosed...

Company

Simcere Pharmaceutical Group Reports 26.4% YOY Revenue Growth in 2022 Financials

Fineline Cube Apr 17, 2023

Simcere Pharmaceutical Group (HKG: 2096), a China-based pharmaceutical company, has reported its financial results for...

Company

Henlius Reports 97.2% YOY Revenue Growth in Q1 2023, Highlighted by Strong Sales of Hanquyou and HaiSiZhuang

Fineline Cube Apr 17, 2023

China-based biopharmaceutical company Henlius (HKG: 2696) has released its financial report for the first quarter...

Policy / Regulatory

Hainan Introduces Management Regulations for Urgently Needed Import Drugs and Devices in Boao Lecheng

Fineline Cube Apr 17, 2023

The Hainan provincial government has issued a Notice on the Management Regulations for Clinically Urgently...

Company Drug

Minghui Pharmaceutical’s MH004 Cream Shows Positive Results in Atopic Dermatitis Phase II Trial

Fineline Cube Apr 17, 2023

China-based Minghui Pharmaceutical has unveiled positive top-line data from a Phase II trial of its...

Company Drug

AffaMed Therapeutics Gets NMPA Approval for Phase III Dextenza Study in Post-Ophthalmic Surgery

Fineline Cube Apr 17, 2023

China-based AffaMed Therapeutics has announced that it has received approval from the National Medical Products...

Posts pagination

1 … 527 528 529 … 657

Recent updates

  • Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
  • Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease
  • Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback
  • China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio
  • Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Company

Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease

Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.